Skip to main content
Fig. 4 | BMC Infectious Diseases

Fig. 4

From: Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice

Fig. 4

Effects of persistent IL2 production induced using an IL2-producing rAAV vector in S. aureus arthritis. a-b, Characteristics of CD4+CD25+FoxP3+ Tregs from peripheral blood and spleen a, Frequency measured during the course of S. aureus arthritis. b Protein expression levels of CD25 and FoxP3 (measured as geometric mean fluorescence (gMFI)), at day 10 after bacterial inoculation. c-g, Frequencies of other lymphocytes measured during the course of S. aureus arthritis in blood and spleen. c, CD4+CD25 Teffs d, CD4+CD25+FoxP3 activated Teffs. e, NK1.1+TCRβ NK f, NK1.1+TCRβ+ NKT g, B cells h, CD8+ T cells. In panels a and c-h, bars show the mean ± standard error of the mean (SEM). In panel b data is shown as median, whiskers = min to max. Statistical calculations were made using Mann-Whitney U-test, *P < 0.05, ****P < 0.0001

Back to article page